MA31336B1 - Inhibiteurs de pi3k alpha a base de pyridopyrimidinone - Google Patents

Inhibiteurs de pi3k alpha a base de pyridopyrimidinone

Info

Publication number
MA31336B1
MA31336B1 MA32314A MA32314A MA31336B1 MA 31336 B1 MA31336 B1 MA 31336B1 MA 32314 A MA32314 A MA 32314A MA 32314 A MA32314 A MA 32314A MA 31336 B1 MA31336 B1 MA 31336B1
Authority
MA
Morocco
Prior art keywords
pyridoperimidineone
pi3k
depend
alpha inhibitors
compounds
Prior art date
Application number
MA32314A
Other languages
Arabic (ar)
English (en)
French (fr)
Inventor
Chris A Buhr
Longcheng Wang
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of MA31336B1 publication Critical patent/MA31336B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/025—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus inorganic Tc complexes or compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Optics & Photonics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA32314A 2007-04-11 2009-10-30 Inhibiteurs de pi3k alpha a base de pyridopyrimidinone MA31336B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91116007P 2007-04-11 2007-04-11
PCT/US2008/004807 WO2008127712A1 (en) 2007-04-11 2008-04-11 Pyrido [2, 3-d] pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer

Publications (1)

Publication Number Publication Date
MA31336B1 true MA31336B1 (fr) 2010-04-01

Family

ID=39642739

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32314A MA31336B1 (fr) 2007-04-11 2009-10-30 Inhibiteurs de pi3k alpha a base de pyridopyrimidinone

Country Status (25)

Country Link
US (2) US20100209340A1 (en:Method)
EP (1) EP2142544B8 (en:Method)
JP (1) JP2010523681A (en:Method)
KR (1) KR20090130104A (en:Method)
CN (1) CN101711249A (en:Method)
AU (1) AU2008239596B2 (en:Method)
BR (1) BRPI0810175A2 (en:Method)
CA (1) CA2683820A1 (en:Method)
CO (1) CO6241119A2 (en:Method)
CR (1) CR11098A (en:Method)
DO (1) DOP2009000242A (en:Method)
EA (1) EA018964B1 (en:Method)
EC (1) ECSP099722A (en:Method)
ES (1) ES2425068T3 (en:Method)
IL (1) IL201209A0 (en:Method)
MA (1) MA31336B1 (en:Method)
MX (1) MX2009010815A (en:Method)
MY (1) MY150747A (en:Method)
NI (1) NI200900183A (en:Method)
NZ (1) NZ579945A (en:Method)
SV (1) SV2009003389A (en:Method)
TN (1) TN2009000389A1 (en:Method)
UA (1) UA101315C2 (en:Method)
WO (1) WO2008127712A1 (en:Method)
ZA (1) ZA200906648B (en:Method)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005316668B2 (en) * 2004-12-13 2012-09-06 Millennium Pharmaceuticals, Inc. Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as RAF kinase inhibitors
GEP20115304B (en) * 2005-10-07 2011-10-10 Exelixis Inc PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα
NZ594630A (en) * 2005-10-07 2013-04-26 Exelixis Inc N-(3-amino-quinoxalin-2-yl)-sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors
WO2008021389A2 (en) 2006-08-16 2008-02-21 Exelixis, Inc. Using pi3k and mek modulators in treatments of cancer
ES2366489T3 (es) 2006-09-15 2011-10-20 Pfizer Products Inc. Compuesto de pirido (2,3-d) piridinona y sus uso como inhibidores de pi3.
HRP20130688T1 (en) 2007-04-10 2013-09-30 Exelixis Inc. Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k alpha
AU2008239655B2 (en) * 2007-04-11 2013-06-20 Exelixis, Inc. Pyrido (2, 3-d) pyrimidin-7-one compounds as inhibitors of PI3k-alpha for the treatment of cancer
EP2350070A1 (en) * 2008-09-30 2011-08-03 Exelixis, Inc. Pyridopyrimidinone inhibitors of pi3k and mtor
WO2011087776A1 (en) * 2009-12-22 2011-07-21 Vertex Pharmaceuticals Incorporated Isoindolinone inhibitors of phosphatidylinositol 3-kinase
TW201139436A (en) 2010-02-09 2011-11-16 Exelixis Inc Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K and mTOR in combination with autophagy inhibitors
CA2812089C (en) 2010-09-14 2020-02-18 Exelixis Inc. Inhibitors of pi3k-delta and methods of their use and manufacture
WO2013056067A1 (en) * 2011-10-13 2013-04-18 Exelixis, Inc. Compounds for use in the treatment of basal cell carcinoma
PE20141794A1 (es) 2011-11-01 2014-12-17 Exelixis Inc N-(3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-metilalaninamida como inhibidor de fosfatidilinositol 3-quinasa para el tratamiento de neoplasias linfoproliferativas

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2937284A (en) * 1958-05-01 1960-05-17 Burroughs Wellcome Co 2, 4-diamino-5, 6-dialkylpyrido (2, 3-d) pyrimidines and method
IL117923A (en) * 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
US7019002B2 (en) * 2001-12-11 2006-03-28 Pharmacia & Upjohn, S.P.A. Pyridopyrimidinones derivatives as telomerase inhibitors
MXPA06012829A (es) * 2004-05-04 2007-01-26 Warner Lambert Co Pirido[2,3-d]pirimidin-7-onas sustituidas con pirrolilo y derivados de las mismas como agentes terapeuticos.
CA2624965A1 (en) * 2005-10-07 2007-04-19 Exelixis, Inc. Pyridopyrimidinone inhibitors of pi3k.alpha.
GEP20115304B (en) * 2005-10-07 2011-10-10 Exelixis Inc PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα
WO2008021389A2 (en) * 2006-08-16 2008-02-21 Exelixis, Inc. Using pi3k and mek modulators in treatments of cancer
ES2366489T3 (es) * 2006-09-15 2011-10-20 Pfizer Products Inc. Compuesto de pirido (2,3-d) piridinona y sus uso como inhibidores de pi3.

Also Published As

Publication number Publication date
DOP2009000242A (es) 2010-04-30
EA018964B1 (ru) 2013-12-30
ES2425068T3 (es) 2013-10-11
UA101315C2 (ru) 2013-03-25
AU2008239596A1 (en) 2008-10-23
CN101711249A (zh) 2010-05-19
AU2008239596B2 (en) 2013-08-15
JP2010523681A (ja) 2010-07-15
MY150747A (en) 2014-02-28
US20100209340A1 (en) 2010-08-19
HK1139941A1 (en) 2010-09-30
CA2683820A1 (en) 2008-10-23
ZA200906648B (en) 2010-04-28
BRPI0810175A2 (pt) 2014-12-30
US20130343988A1 (en) 2013-12-26
MX2009010815A (es) 2009-10-29
EP2142544B8 (en) 2013-07-03
CO6241119A2 (es) 2011-01-20
KR20090130104A (ko) 2009-12-17
NZ579945A (en) 2012-05-25
EP2142544B1 (en) 2013-05-22
EA200970936A1 (ru) 2010-02-26
IL201209A0 (en) 2010-05-31
TN2009000389A1 (en) 2010-12-31
ECSP099722A (es) 2009-12-28
NI200900183A (es) 2010-10-05
CR11098A (es) 2010-01-27
WO2008127712A1 (en) 2008-10-23
EP2142544A1 (en) 2010-01-13
SV2009003389A (es) 2010-04-27

Similar Documents

Publication Publication Date Title
MA31336B1 (fr) Inhibiteurs de pi3k alpha a base de pyridopyrimidinone
EA201070618A1 (ru) 4-пиразолил-n-арилпиримидин-2-амины и 4-пиразолил-n-гетероарилпиримидин-2-амины в качестве ингибиторов киназ janus
MA31167B1 (fr) Inhibiteurs de l'activite de akt
MY148851A (en) Dihydropyridine derivatives as useful as protein kinase inhibitors
MA33119B1 (fr) Derives de benzofuranyle utilises comme inhibiteurs de la glucokinase
MX2009012066A (es) Imidazopirinas sustituidas como inhibidoras de cinasa de lipido p13k.
EA200870218A1 (ru) Замещенные имидазольные производные, композиции и способы применения в качестве ингибиторов ртразы
ATE525375T1 (de) Hemmer von janus-kinasen und/oder 3- phosphoinositid-abhängiger protein-kinase 1
MA27933A1 (fr) Inhibiteurs de l'activite de akt
BRPI0510177A (pt) heterociclos monocìclicos como inibidores de cinase
ATE497496T1 (de) 2,4-pyridimediamon-derivate als hemmer von jak- kinasen zur behandlung von autoimmunerkrankungen
MXPA05010711A (es) Compuestos y composiciones novedosos como inhibidores de proteina-quinasa.
TW200714604A (en) Substituted heterocycles and the uses thereof
MX2009006195A (es) Compuestos basados en 4-fenil-6-(2,2,2-trifluoro-1-feniletoxi)piri midina y metodos de su uso.
EA200800664A1 (ru) Производные пирролопиримидина в качестве ингибиторов syk
MX2009004623A (es) Imidazopiridazinas como inhibidores de la lipido cinasa pi3k.
TW200634012A (en) 3-amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents
EA201500403A1 (ru) Соединения, активирующие теломеразу, и способы их применения
EA200801362A1 (ru) Пиримидинил бензотиофеновые соединения
MA33155B1 (fr) Composes organiques et leurs utilisations
EA201291055A1 (ru) Ингибиторы протеинтирозинкиназной активности и их применение для лечения глазных заболеваний
EA201170344A1 (ru) Азаиндольные ингибиторы iap
EA200800014A1 (ru) Аминохинолиновые и аминохиназолиновые модуляторы киназы
MA31562B1 (fr) Macrocycles et leurs utilisations
MX2009012079A (es) Compuestos heterociclicos condensados como inhibidores de proteina cinasas.